Breast cancer - managing FH
Exam Tips
- In OSCEs, take a structured 3-generation pedigree including paternal relatives; paternal transmission is clinically important.
- Single first- or second-degree relative diagnosed after age 40 years, with no red flags, is often suitable for primary-care reassurance and lifestyle advice.
- Red flags prompting referral include breast cancer <40 years in a first-degree relative, male breast cancer, bilateral disease, breast-plus-ovarian pattern, and multiple affected relatives.
- State chemoprevention doses precisely: tamoxifen 20 mg once daily for 5 years (typically premenopause), anastrozole 1 mg once daily for 5 years (postmenopause).
- Always mention safety counselling: VTE/endometrial risk with tamoxifen and bone loss/fracture risk with aromatase inhibitors.
Definition
Familial breast cancer management refers to risk stratification and prevention in people (from age 16 years) who are concerned that their family history indicates increased breast cancer susceptibility. It includes structured pedigree assessment, identification of red-flag cancer patterns suggestive of inherited pathogenic variants (for example BRCA1/BRCA2), and tailored prevention with lifestyle advice, enhanced screening, chemoprevention, and selected risk-reducing surgery.
Pathophysiology
Most breast cancers are sporadic, but about 5-10% are hereditary and driven by germline pathogenic variants in tumour-suppressor or DNA-repair genes. BRCA1/BRCA2-associated disease is linked to defective homologous recombination DNA repair, causing genomic instability and earlier/multiple primary cancers; other genes (for example PALB2, ATM, CHEK2, TP53, PTEN, STK11, CDH1) confer variable penetrance and broader multi-organ cancer phenotypes. Familial risk is probabilistic rather than deterministic: risk rises with younger age at diagnosis in relatives, bilateral disease, male breast cancer, and clustering of related cancers (notably ovarian, pancreatic, prostate), while hormonal, metabolic, and lifestyle exposures further modify absolute risk.
Risk Factors
- First-degree relative with breast cancer (risk increases further with more affected relatives and younger age at diagnosis)
- Male breast cancer in the family
- Bilateral breast cancer in a relative, especially if first primary diagnosed before 50 years
- Family history combining breast and ovarian cancer
- Multiple affected relatives on one lineage, including paternal side clustering
- Known familial pathogenic variant (for example BRCA1, BRCA2, TP53, PALB2, CHEK2, ATM, PTEN, STK11, CDH1)
- Ashkenazi Jewish ancestry with compatible family history
- Related early-onset tumours in family (for example pancreatic or prostate cancer, sarcoma <45 years, glioma, childhood adrenal cortical carcinoma)
- Alcohol intake (dose-related increase in risk)
- Low physical activity
- Post-menopausal overweight/obesity
- Prolonged combined oral contraceptive use
- Hormone replacement therapy use (risk varies by regimen and duration)
- Ionising radiation exposure (especially at younger ages)
Clinical Features
Symptoms
- Usually asymptomatic; presentation is concern about family history and future risk
- Anxiety, cancer worry, or repeated requests for risk clarification
- Occasionally concurrent breast symptoms (for example new lump, nipple change), which require urgent standard breast assessment pathways rather than family-history-only management
Signs
- No specific physical signs of familial risk in most patients
- Pedigree red flags on history: early-onset cases, bilateral disease, male breast cancer, breast-plus-ovarian pattern, paternal clustering
- Possible syndromic clues in rare hereditary syndromes (for example mucocutaneous/hamartomatous features in PTEN/STK11-related disorders)
Investigations
Management
Lifestyle Modifications
- Risk communication and shared decision-making using absolute risk, not family history alone
- Limit alcohol intake, increase regular physical activity, and optimize weight (especially post-menopause)
- Smoking cessation support and general cancer-prevention counselling
- Review need, type, and duration of exogenous hormones (COCP/HRT) in context of familial risk
- Psychological support and safety-netting for new breast symptoms
- Use visual pedigree aids in counselling (see Figure: example 3-generation pedigree used in genetics clinics)
Pharmacological Treatment
Selective oestrogen receptor modulator (chemoprevention)
- Tamoxifen 20 mg orally once daily for 5 years (typically premenopausal moderate/high-risk women)
Discuss benefits versus harms before prescribing. Avoid in pregnancy; advise effective non-hormonal contraception during treatment and for a period after stopping. Use caution/avoid with personal history of venous thromboembolism; increased risk of VTE and (in women with uterus) endometrial pathology. Review interacting medicines (for example potent CYP2D6 inhibitors may reduce efficacy).
Aromatase inhibitor (chemoprevention, postmenopausal)
- Anastrozole 1 mg orally once daily for 5 years
For postmenopausal women at moderate/high familial risk when appropriate. Adverse effects include arthralgia, hot flushes, and bone mineral density loss; assess fracture risk and consider bone protection strategies. Not suitable in pregnancy or in premenopausal ovarian function without specialist advice.
Alternative SERM in postmenopause (specialist use)
- Raloxifene 60 mg orally once daily for 5 years
Option in selected postmenopausal women when tamoxifen/anastrozole are unsuitable. Contraindicated in active or past VTE; can increase thromboembolic risk.
Surgical / Interventional
- Risk-reducing bilateral mastectomy in carefully selected very high-risk individuals after specialist genetic and breast multidisciplinary counselling
- Risk-reducing bilateral salpingo-oophorectomy in BRCA carriers primarily to reduce ovarian cancer risk, with additional breast-risk impact in some groups
- Surgery is not first-line for most people with family history alone and requires informed consent about irreversible effects and complications
Complications
- Development of breast cancer despite surveillance/prevention
- Second primary or bilateral breast cancer in high-risk mutation carriers
- Associated non-breast cancers in hereditary syndromes (for example ovarian, pancreatic, prostate, sarcoma, brain, thyroid, uterine depending on genotype)
- Adverse effects of chemoprevention (for example VTE/endometrial effects with tamoxifen; bone loss with aromatase inhibitors)
- Psychological morbidity (health anxiety, decisional conflict, family communication stress)
Prognosis
Most people with a limited family history (for example a single older affected relative) remain near population risk and can usually be managed in primary care with reassurance and risk-factor modification. Prognosis is driven by underlying genetic risk category and uptake of preventive strategies: structured surveillance, timely genetics referral, and appropriate chemoprevention/surgery can materially reduce cancer incidence and improve stage at diagnosis.
Sources & References
🏥BMJ Best Practice(1)
✅NICE Guidelines(1)
- Breast cancer - managing FH[overview]